BMS' Q212 Results Show Prosperous Future

BMI View: Bristol-Myers Squibb (BMS)'s recent acquisition of Amylin Pharmaceuticals, promising data from immuno-oncology clinical trials, positive trends in a portfolio of newly marketed key brands, new drugs on the brink of approval and an 8% global sales increase, excluding patent expiries, highlights an extremely positive outlook for the company. This, in addition to a weak emerging markets presence, means we maintain our view that BMS has very strong growth potential and will not experience long-term negative effects to its revenue compared to its competitors.

To read the full article, please choose one of the following options: